CytomX Therapeutics (CTMX) Set to Announce Earnings on Thursday

CytomX Therapeutics (NASDAQ:CTMX) is anticipated to post its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect CytomX Therapeutics to post earnings of ($0.09) per share and revenue of $10.38 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Thursday, November 5, 2026 at 5:00 PM ET.

CytomX Therapeutics (NASDAQ:CTMX) last released its quarterly earnings data on Thursday, August 6th. The biotechnology company reported ($0.09) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.01). The firm had revenue of $1.42 million for the quarter, compared to the consensus estimate of $12.39 million. CytomX Therapeutics had a negative net margin of 435.21% and a negative return on equity of 38.46%. On average, analysts expect CytomX Therapeutics to post ($0.40) EPS for the current fiscal year and ($0.52) EPS for the next fiscal year.

CytomX Therapeutics Stock Up 2.2%

Shares of CTMX opened at $2.36 on Thursday. The company has a market capitalization of $514.24 million, a P/E ratio of -4.72 and a beta of 2.21. CytomX Therapeutics has a twelve month low of $2.16 and a twelve month high of $8.21. The firm has a 50 day moving average of $2.87 and a 200 day moving average of $3.89.

Analyst Ratings Changes

Several research analysts have recently weighed in on the company. Wall Street Zen cut CytomX Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, August 23rd. Weiss Ratings reaffirmed a “sell (d)” rating on shares of CytomX Therapeutics in a research report on Friday, September 11th. Guggenheim dropped their price objective on CytomX Therapeutics from $15.00 to $14.00 and set a “buy” rating on the stock in a research report on Monday, August 10th. Cantor Fitzgerald reiterated an “overweight” rating on shares of CytomX Therapeutics in a report on Tuesday, October 13th. Finally, Zacks Research lowered CytomX Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, August 19th. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $11.90.

About CytomX Therapeutics

CytomX Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing cancer medicines designed to be activated selectively within the tumor microenvironment. The company’s approach is intended to improve the precision of treatment by limiting activity in healthy tissues while enabling therapeutic effects at tumor sites.

CytomX’s research is based on its Probody therapeutic platform, which uses molecular masking and tumor-associated protease activity to conditionally activate antibody-based medicines.